BRYNJA BOWMAN: Open Payments
NPI 1083197644 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,613 in 58 payments from 13 companies in 2025. Trend: 2023 $30 · 2024 $1,026 · 2025 $1,613
Food & beverage: $1,613
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $466 |
| Phathom Pharmaceuticals, Inc. | 5 | $255 |
| Madrigal Pharmaceuticals | 5 | $193 |
| Janssen Biotech, Inc. | 8 | $171 |
| Gilead Sciences, Inc. | 2 | $165 |
| Novo Nordisk Inc | 1 | $118 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| QOL Medical, LLC | 2 | $45 |
| Ipsen Biopharmaceuticals, Inc | 1 | $33 |
Products named: VOQUEZNA, REZDIFFRA, RINVOQ, TREMFYA, SKYRIZI, MAVYRET, DUPIXENT, XIFAXAN.
Industry payments across NV — which companies pay providers there.
